As a World Health Assembly meeting nears, several European countries are proposing numerous changes that patient advocates argue would water down a resolution designed to create more transparency around prescription drug pricing.

At a planning session earlier this week, nearly a dozen countries — particularly Germany, Denmark, the U.K., and Sweden — offered a bevy of subtle and not-so-subtle suggestions for softening language used to describe pricing as well as for disclosing R&D costs, patent holdings, and clinical trial results, among other things. A final version, which must still be crafted, will be vetted at the WHA meeting that starts on May 20 in Geneva.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • And, this change was pretty big.

    Opt 1.3 [Require as a condition of registration for medicines, vaccines cell
    and gene-based therapies and other relevant technologies;

    a) Annual Reports on sales revenues, prices and units sold,

    b) Annual Reports on marketing costs incurred for each registered product
    or procedure,

    c) The R&D costs directly associated with each clinical trial used to support
    the registration of a product or procedure, separately, and

    d) All grants, tax credits or any other public sector subsidies and incentives
    relating to the initial regulatory approval and annually on the subsequent
    development of a product or procedure; (DEL USA, Australia, Denmark)]

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy